Sanmei Wang

Nanjing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Machine Learning-Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma.

Machine Learning-Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma.

Journal: Cancer science
Published: June 08, 2026

Circulating NK-cell counts improve prognostic stratification of the PINKE model in extranodal NK/T-cell lymphoma: a retrospective cohort study.

Circulating NK-cell counts improve prognostic stratification of the PINKE model in extranodal NK/T-cell lymphoma: a retrospective cohort study.

Journal: Leukemia research
Published: May 08, 2026

Survival Outcomes and Prognostic Factors in Patients With Primary Central Nervous System Low-Grade B-Cell Lymphoma: A Population-Based Cohort Study.

Survival Outcomes and Prognostic Factors in Patients With Primary Central Nervous System Low-Grade B-Cell Lymphoma: A Population-Based Cohort Study.

Journal: Cancer medicine
Published: May 07, 2026

Renal Dysfunction in Patients with CML on Long-Term First-Line TKI Therapy: A Single-Center Analysis.

Renal Dysfunction in Patients with CML on Long-Term First-Line TKI Therapy: A Single-Center Analysis.

Journal: The oncologist
Published: April 01, 2026

A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia.

A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia.

Journal: Annals of medicine
Published: March 09, 2026

Real-world effectiveness of zanubrutinib plus salvage chemotherapy in relapsed or refractory double-expressor DLBCL.

Real-world effectiveness of zanubrutinib plus salvage chemotherapy in relapsed or refractory double-expressor DLBCL.

Journal: Annals of hematology
Published: January 20, 2026

Dose-reduced (24 Gy) involved-site radiotherapy combined with rituximab in early-stage non-gastric mucosa-associated lymphoid tissue lymphoma: a prospective phase II trial.

Dose-reduced (24 Gy) involved-site radiotherapy combined with rituximab in early-stage non-gastric mucosa-associated lymphoid tissue lymphoma: a prospective phase II trial.

Journal: Leukemia
Published: December 25, 2025

A lipid nanoparticle-based peptide-proteolysis-targeting chimera degrades BCL6 for diffuse large B-cell lymphoma treatment.

A lipid nanoparticle-based peptide-proteolysis-targeting chimera degrades BCL6 for diffuse large B-cell lymphoma treatment.

Journal: Discover oncology
Published: December 06, 2025

Progression of disease within 6 months: revised early disease progression threshold for ENKTL.

Progression of disease within 6 months: revised early disease progression threshold for ENKTL.

Journal: Leukemia & lymphoma
Published: June 11, 2025

CD96 as a therapeutic target for CAR T cell therapy in acute myeloid leukemia.

CD96 as a therapeutic target for CAR T cell therapy in acute myeloid leukemia.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: February 14, 2025

HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma.

HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma.

Journal: Biomedicines
Published: January 12, 2022

Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells.

Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells.

Journal: Cytotherapy
Published: August 05, 2021
Showing 1-12 of 21

Last Updated: 09/26/2026